Several controlled and uncontrolled trials have shown that the use of pulmonary arterial hypertension (PAH)-specific drugs might be useful in inoperable CTEPH.\textsuperscript{1, 2} Riociguat is currently the only PAH-specific drug also approved for inoperable CTEPH.\textsuperscript{1}

Recently, balloon pulmonary angioplasty (BPA) has emerged as an alternative treatment option for patients with inoperable CTEPH or persistent PH after surgery. Several reports now support the efficacy and safety of BPA. The haemodynamic benefits were summarised in a recent review article, with an overall reduction in mean pulmonary arterial pressure of 12–21 mmHg from baseline, and a mortality rate of 0.0%–3.4% after 2–5 angioplasty sessions.\textsuperscript{4} Sustained haemodynamic improvements, almost to within the normal range, have been reported up to 3.5 years after BPA.\textsuperscript{2} Severe and fatal complications, including mostly pulmonary vessel injury, may be minimised with not only accumulation of experience but also refinements in technique. An old approach with targeting only one lobe during each session and full balloon sizing increased the incidence of complications. Approaching with undersized balloon may reduce or prevent vessel injury but is less effective in each individual segment, so several segments and lobes are targeted at one session. BPA has the potential to become a key treatment strategy for patients with inoperable CTEPH. However, the indications and limitations of BPA have not been fully established. An international registry contributed by specialised centres is needed for further investigations.

REFERENCES


31 EPIDEMIOLOGY OF HEART FAILURE IN SOUTH ASIA

Amit Roy. All India Institute of Medical Sciences, New Delhi, India

10.1136/heartasia-2019-apahff.32

South Asia has seen rapid epidemiological transition in the last two decades with a rapid rise in cardiovascular diseases, which have emerged as the leading cause of mortality in this region. In India the leading cause of disability adjusted life years is ischaemic heart disease which has seen a 104% increase between 1990 and 2016.\textsuperscript{1} Similarly the burden of obesity, hypertension and diabetes mellitus has increased markedly over this time and with poor control rates for these risk factors leading to a fertile soil for rise in incidence of heart failure.\textsuperscript{2} In the absence of active surveillance mechanisms reliable estimates of heart failure burden is missing. However, one study estimates it to the tune of 4.6 million which is probably a severe under-estimate given the risk factor burden.\textsuperscript{3} The study of the heart failure patients in two large registries, INTER-CHF and Trivandrum Heart Failure Registry,\textsuperscript{4} revealed disturbingly high mortality rates of 23% and 31%, respectively. This was much higher than that of patients from other low and middle income countries.\textsuperscript{4} The chief driver of this mortality seems to be suboptimal medical management of these patients with a large percentage not receiving beta-blockers and renin-angiotensin aldosterone inhibitors; drugs known to improve survival. Thus, quality improvement program using guideline-directed medical therapy will go a long way in improving survival of these patients.

31 FABRY DISEASE IN EAST ASIA

1 Alex PW Lee, 2 Kevin KH Kam, 3 Erik Fung, 4 Josie Chow, 5 Yiting Fan, 6 Polakit Teekakirikul, 7 Jais X, 8 Princess Margaret Hospital, the Chinese University of Hong Kong, Hong Kong SAR; 9 Department of Health, Hong Kong SAR; 10 Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR; 11 Department of Health, New Dehli, India

10.1136/heartasia-2019-apahff.31

Fabry disease (FD) is an X-linked inherited lysosomal storage disorder that results from mutations in the α-galactosidase A gene (GLA), leading to deficient α-galactosidase A (α-GaLA) activity and subsequent accumulation of globotriaosylceramide (Gb3) in a variety of tissues.\textsuperscript{1} The estimated prevalence of classic FD in males ranges from 1:8000 to 1:117,000,\textsuperscript{2} likely an underestimation given its non-specific manifestations. The mutation IVS4 +919G>A (c.936 +919G>A) associated with founder effect in East Asia was first described in Taiwan.\textsuperscript{3} Left ventricular hypertrophy (LVH) is a hallmark of the later-onset cardiac variant of FD. The prevalence of FD among adult patients with LVH is unknown. In an ongoing FD screening programme from August 2017 through 2018, we measured plasma α-GaLA activity using dried blood spot testing in 143 consecutive male patients with LVH (defined as maximal LV wall thickness ≥13 mm on echocardiography). Patients with low α-GaLA activity underwent GLA gene sequencing analysis and endomyocardial biopsy. Four of 143 patients with LVH (2.8%) had low plasma α-GaLA activity (0.4±0.2 μmol/L whr/ hr; 3%–15% of the mean in normal controls). All 4 unrelated patients (aged 53–74 years) shared the same IVS4 +919G>A mutation with maximal LV wall thickness ranging from 14–29 mm. None had extracardiac manifestations but presented with hypertrophic cardiomyopathy, hypertension, heart failure, or aortic stenosis. Endomyocardial biopsy performed in one patient showed hypertrophic cardiomyocytes with sarcoplasmic vacuolisation. Our results suggest that FD should be considered as a cause of LVH in adult men even when other more usual causes of LVH are present.

REFERENCES

Abstracts

REFERENCES


Hypertrophic cardiomyopathy (HCM) is a prevalent heritable cardiac disorder, characterised by unexplained left ventricular hypertrophy (LVH) with the triad of myocyte hypertrophy, disarray, and interstitial fibrosis. Such pathological hallmarks impact diastolic function and contribute to adverse clinical outcomes: arrhythmias, progressive heart failure and sudden cardiac death. To date, none of the available armamentaria has been shown to fundamentally modify disease progression, or to benefit genotype-positive, phenotype-negative or preclinical HCM patients. Multiple genetic studies have identified considerable numbers of HCM-causing mutations in human sarcomere protein genes, and mice engineered to carry such human mutations recapitulated key phenotypes of HCM. This has provided remarkable opportunities to identify the novel therapeutics at the molecular levels, and allowed us to integrate gene-based diagnostics into clinical management of preclinical HCM. Studies in HCM mouse models have illustrated the importance of activated transforming growth factor beta (TGF-β) pathway in the early development of HCM. Treatment with either TGF-β neutralising antibodies or with angiotensin II type 1 receptor antagonist, losartan, was shown to retard and prevent HCM development in mouse models. Lately, MYK-461, the first allosteric inhibitor of the cardiac myosin adenosine triphosphate (ATPase), has been shown to reduce left ventricular contractility and attenuate HCM development in mouse models. Clinical trials are currently underway to evaluate and investigate these two promising disease-modifying therapies in HCM patients.

REFERENCES


